BC Week In Review | Aug 22, 2016
Clinical News

AC5 Surgical Hemostatic Device: Clinical trial data

Top-line data from a single-blind, Irish clinical trial in 46 patients with bleeding wounds due to >=2 skin lesion excisions showed that topical AC5 administered by the AC5 Surgical Hemostatic Device met the primary endpoint...
BC Innovations | Mar 17, 2016
Distillery Therapeutics

Therapeutics: Adenylate cyclase 5 (AC5)

Cardiovascular disease INDICATION: Ischemia / reperfusion injury Mouse and pig studies suggest inhibiting AC5 could help treat ischemia/reperfusion injury. In a mouse model of coronary artery occlusion, heart-specific knockout of AC5 decreased infarct size compared...
BC Week In Review | Jul 15, 2013
Company News

Arch Therapeutics deal

Arch Therapeutics (formerly Almah Inc.) reverse-merged with Arch Biosurgery Inc., with Arch Therapeutics remaining as the surviving entity. The company's AC5 is in preclinical development to achieve hemostasis in minimally invasive and open surgical procedures....
Items per page:
1 - 3 of 3